NanoString introduces new assay for leukemia fusion gene analysis

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the availability of a comprehensive multiplexed assay for the simple and cost-effective analysis of fusion genes linked to leukemia. The new tool is expected to greatly aid the ability of cancer researchers to characterize these genetic abnormalities.

The nCounter® Leukemia Fusion Gene Panel covers 25 specific isoforms from seven fusion gene families associated with three types of leukemia: acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and acute lymphocytic (lymphoblastic) leukemia (ALL). The multiplexed assay can be performed at a fraction of the cost associated with traditional analysis methods such as fluorescence in situ hybridization (FISH), karyotyping, or polymerase chain reaction (PCR). Since the assay is compatible with a variety of specimens, including archived formalin-fixed, paraffin-embedded (FFPE) samples, it requires less hands-on time and technical expertise than other available analysis methods.

Mohamed E. Salama, M.D., Assistant Medical Director, Hematopathology Laboratory at ARUP Laboratories and an Associate Professor of Pathology at the University of Utah School of Medicine, was an early access customer for the new panel. "We are very impressed with the performance of the nCounter Leukemia Fusion Gene Panel, particularly its linearity and reproducibility," commented Dr. Salama. "The ability to analyze paraffin embedded samples is a huge advantage for translational cancer research, as is the fact that no enzymatic steps or amplification are required. There is really nothing else like this available."

FFPE samples are the most common form of archived tumor specimens, and it is estimated that 400 million samples are stored in tissue banks worldwide. The nCounter Leukemia Fusion Gene Panel enables researchers to study these high-value archived samples in great detail, using a simple and robust platform.

"The Leukemia Fusion Gene Panel is the latest example of how the nCounter platform is aiding researchers in the investigation of genes linked to cancer," said Barney Saunders, Ph.D., Chief Commercial Officer of NanoString Technologies. "The assay measures 25 fusion gene transcripts and the expression levels of 23 leukemia-associated mRNAs to provide an extensive molecular profile of each sample."

The nCounter Analysis System is a fully automated digital detection and counting system with a very simple workflow. The assay kits contain all of the reagents and consumables required to conduct an experiment. Minimal sample input requirements and compatibility with a variety of sample types, extends the utility of the platform. In addition to gene expression assays, NanoString provides assays for copy number variation and miRNA analysis. The nCounter Analysis System and Leukemia Fusion Gene Panel are currently available for Research Use Only.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoString Technologies. (2019, June 20). NanoString introduces new assay for leukemia fusion gene analysis. News-Medical. Retrieved on July 14, 2024 from

  • MLA

    NanoString Technologies. "NanoString introduces new assay for leukemia fusion gene analysis". News-Medical. 14 July 2024. <>.

  • Chicago

    NanoString Technologies. "NanoString introduces new assay for leukemia fusion gene analysis". News-Medical. (accessed July 14, 2024).

  • Harvard

    NanoString Technologies. 2019. NanoString introduces new assay for leukemia fusion gene analysis. News-Medical, viewed 14 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
NanoString announces key initiatives to expand market for nCounter Analysis System, related product portfolio